Literature DB >> 19399581

Pneumocystis jiroveci pneumonia as an atypical presentation of X-linked agammaglobulinemia.

Hirokazu Kanegane, Takashi Nakano, Yoshiki Shimono, Meina Zhao, Toshio Miyawaki.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19399581     DOI: 10.1007/s12185-009-0322-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  8 in total

1.  Kinase mutant Btk results in atypical X-linked agammaglobulinaemia phenotype.

Authors:  H B Gaspar; M Ferrando; I Caragol; M Hernandez; J M Bertran; X De Gracia; T Lester; C Kinnon; E Ashton; T Espanol
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

Review 2.  Genetic analysis of patients with defects in early B-cell development.

Authors:  Mary Ellen Conley; Arnon Broides; Vivian Hernandez-Trujillo; Vanessa Howard; Hirokazu Kanegane; Toshio Miyawaki; Sheila A Shurtleff
Journal:  Immunol Rev       Date:  2005-02       Impact factor: 12.988

3.  Pneumocystis carinii pneumonia in an infant with X-linked agammaglobulinemia.

Authors:  A Alibrahim; M Lepore; M Lierl; A Filipovich; A Assaád
Journal:  J Allergy Clin Immunol       Date:  1998-04       Impact factor: 10.793

4.  Infant pneumonitis associated with cytomegalovirus, Chlamydia, Pneumocystis, and Ureaplasma: follow-up.

Authors:  D M Brasfield; S Stagno; R J Whitley; G Cloud; G Cassell; R E Tiller
Journal:  Pediatrics       Date:  1987-01       Impact factor: 7.124

5.  Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia.

Authors:  Klára Sochorová; Rudolf Horváth; Daniela Rozková; Jirí Litzman; Jirina Bartunková; Anna Sedivá; Radek Spísek
Journal:  Blood       Date:  2006-11-07       Impact factor: 22.113

6.  Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia.

Authors:  Hiromichi Taneichi; Hirokazu Kanegane; Mostafa Mohamed Sira; Takeshi Futatani; Kazunaga Agematsu; Masahiro Sako; Hideo Kaneko; Naomi Kondo; Tsuneyasu Kaisho; Toshio Miyawaki
Journal:  Clin Immunol       Date:  2008-02       Impact factor: 3.969

7.  A case of Pneumocystis jiroveci pneumonia in X-linked agammaglobulinaemia treated with immunosuppressive therapy: a lesson for immunologists.

Authors:  Maria Caterina Sirianni; Chiara Atzori; Wladimiro De Santis; Cinzia Milito; Antonella Esposito; Marco Marziali; Maria Livia Bernardi; Antonietta Cargnel; Fernando Aiuti
Journal:  Int Arch Allergy Immunol       Date:  2006-03-20       Impact factor: 2.749

8.  Pneumocystis carinii pneumonitis in young immunocompetent infants.

Authors:  S Stagno; L L Pifer; W T Hughes; D M Brasfield; R E Tiller
Journal:  Pediatrics       Date:  1980-07       Impact factor: 7.124

  8 in total
  6 in total

1.  X-linked agammaglobulinemia presenting as polymicrobial pneumonia, including Pneumocystis jirovecii.

Authors:  Artemio M Jongco; Jonathan D Gough; Kyle Sarnataro; David W Rosenthal; Joanne Moreau; Punita Ponda; Vincent R Bonagura
Journal:  Ann Allergy Asthma Immunol       Date:  2013-11-09       Impact factor: 6.347

2.  Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib.

Authors:  Inhye E Ahn; Theresa Jerussi; Mohammed Farooqui; Xin Tian; Adrian Wiestner; Juan Gea-Banacloche
Journal:  Blood       Date:  2016-08-08       Impact factor: 22.113

3.  Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.

Authors:  Georgios Chamilos; Michail S Lionakis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

4.  Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.

Authors:  Marissa A Zarakas; Jigar V Desai; Georgios Chamilos; Michail S Lionakis
Journal:  Curr Fungal Infect Rep       Date:  2019-07-05

Review 5.  Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic.

Authors:  Petra Langerbeins; Barbara Eichhorst
Journal:  Acta Haematol       Date:  2021-02-25       Impact factor: 2.195

Review 6.  Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.

Authors:  Justin T Low; Katherine B Peters
Journal:  CNS Oncol       Date:  2020-03-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.